Hikma Pharmaceutical | HIK - Equity Capital And Reserves



Hikma Pharmaceutical reported $2.32B in Equity Capital and Reserves for its fiscal semester ending in December of 2024.


Equity Capital And Reserves Change Date
Almirall EUR 1.46B 37.19M Jun/2025
argenx SE 6.1B 597.47M Jun/2025
AstraZeneca USD 44.72B 3.68B Jun/2025
Autolus Therapeutics Ltd 346.46M 24.64M Jun/2025
Bayer EUR 30.5B 2.08B Jun/2025
Fresenius EUR 18.94B 465M Jun/2025
Galapagos EUR 2.64B 104.07M Jun/2025
Genmab DKK 5.3B 6M Jun/2025
GlaxoSmithKline GBP 14.35B 197M Jun/2025
GRIFOLS EUR 7.6B 1.96B Jun/2025
Hikma Pharmaceutical USD 2.32B 35M Dec/2024
Lonza CHF 9.33B 23M Dec/2024
Merck EUR 28.26B 1.64B Jun/2025
Orion EUR 919.6M 147.2M Jun/2025
Recordati EUR 1.87B 107.18M Jun/2025
Roche Holding CHF 36.16B 3.28B Dec/2024
Sanofi 70.28B 3.8B Jun/2025
UCB EUR 10.03B 1.08B Dec/2024